Trial Identifier: | D5660C00004 |
Sponsor: | AstraZeneca |
Collaborator: |
MedImmune Inc.
|
NCTID:: | NCT02499328 |
Start Date: | August 2015 |
Primary Completion Date: | February 2020 |
Study Completion Date: | March 2025 |
Condition: | Cancer - Other |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
Country | Location |
---|---|
BE | Antwerpen, BE, 2020 |
BE | Brussels, BE, 1000 |
BE | Bruxelles, BE, 1200 |
BE | Edegem, BE, 2650 |
BE | Namur, BE, 5000 |
DE | Berlin, DE, 12200 |
DE | Dresden, DE, 1307 |
DE | Frankfurt, DE, 60488 |
DE | Hamburg, DE, 20246 |
DE | Hannover, DE, 30625 |
DE | Jena, DE, 07743 |
DE | Köln, DE, 50670 |
DE | München, DE, 81675 |
ES | Barcelona, ES, 08035 |
ES | Hospitalet deLlobregat, ES, 08907 |
ES | Madrid, ES, 28040 |
ES | Madrid, ES, 28041 |
ES | Toledo, ES, 45004 |
GB | Birmingham, GB, B15 2TH |
GB | London, GB, SW3 6JB |
GB | London, GB, SE1 9RT |
GB | Manchester, GB, M20 4BX |
GB | Taunton, GB, TA1 5DA |
IT | Milano, IT, 20133 |
US, AL | Birmingham, AL, US, 35294 |
US, CA | Duarte, CA, US, 91010 |
US, CA | La Jolla, CA, US, 92093 |
US, CA | Los Angeles, CA, US, 90089 |
US, CA | Los Angeles, CA, US, 90024 |
US, CA | Orange, CA, US, 92868-3298 |
US, CA | San Francisco, CA, US, 94158 |
US, CO | Denver, CO, US, 80218 |
US, FL | Plantation, FL, US, 33324 |
US, FL | Sarasota, FL, US, 34232 |
US, IN | Lafayette, IN, US, 47905 |
US, MA | Boston, MA, US, 02111 |
US, MI | Detroit, MI, US, 48201 |
US, MT | Billings, MT, US, 59101 |
US, NJ | Morristown, NJ, US, 07960 |
US, OH | Cincinnati, OH, US, 45267-2827 |
US, TX | Houston, TX, US, 77030 |
US, VA | Fairfax, VA, US, 22031 |
US, WA | Seattle, WA, US, 98109 |